Key result
Oral dronedarone at 20 mg/kg twice daily significantly lengthened the PQ interval and lowered mean blood pressure in conscious dogs, with minimal effects on cardiac inotropy and lusitropy.
Why the study?
Does oral dronedarone alter cardiac function, blood pressure, and electrocardiogram parameters in healthy conscious dogs?
RCT (n=6)
Randomized
No
Does oral dronedarone alter cardiac function, blood pressure, and electrocardiogram parameters in healthy conscious dogs?
Effect estimate: 21.7% increase
p-value: p=<0.001
In healthy conscious dogs, short-term oral dronedarone produced negative dromotropy and lowered blood pressure with minimal effect on cardiac contractility and relaxation.
Dronedarone's AV nodal and BP effects in dogs warrant caution in veterinary use; leaves open translation to human AF or HF management.
Dronedarone is a multichannel blocking antiarrhythmic drug that has been used for management of atrial fibrillation in humans, but the data in veterinary medicine are inadequate. The objective of this study was to determine the short-term effects of oral dronedarone on cardiac inotropy and lusitropy, blood pressure and electrocardiogram (ECG) in healthy dogs. A total of 6 beagle dogs were instrumented with telemetry units and sono-micrometry crystals to obtain left ventricular pressure-volume relationship, mean blood pressure (MBP) and ECG. Dogs were given orally dronedarone (20 mg/kg, twice per day) for 7 days. All parameters were obtained hourly at 4-8 hr after the first dose and at 12-, 96- (day 4) and 168-hr (day 7) after dosing. The results showed that dronedarone had no effect on inotropy and lusitropy, while it significantly lengthened PQ interval (P<0.001) and lowered MBP (P<0.05). Dronedarone also tended to reduce cardiac output (P=0.237) and heart rate (P=0.057). These results suggested that short-term effects of oral dronedarone administration at a dose of 20 mg/kg, twice per day, produced negative dromotropy with minimal effect on cardiac function in conscious dogs.
No takes yet. Share an insight, caveat, or question.
Saengklub et al. (2016) conducted an RCT in Healthy (n=6). Dronedarone vs. Placebo was evaluated on PQ interval at day 4 (21.7% increase, p=<0.001). Oral dronedarone at 20 mg/kg twice daily significantly lengthened the PQ interval and lowered mean blood pressure in conscious dogs, with minimal effects on cardiac inotropy and lusitropy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: